Before we knew, we’re celebrating Utrecht Health Seed Fund’s first anniversary!
And what a year it has been. We can’t express how proud we are of our exceptional portfolio companies and the talented entrepreneurs and scientists driving these ventures:
– TargED Biopharmaceuticals is developing a next generation clot-busting drug with unique properties, focusing on Acute Ischemic Stroke and Thrombotic Thrombocytopenic Purpura (TTP);
– Moveshelf is building a unique software platform for clinical movement analysis, targeted at severe movement disorders such as Cerebral Palsy;
– NTrans Technologies is advancing their gene editing platform to target Duchenne Muscular Dystrophy; and
– SentryX is building a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain.
We are continuously scouting and screening new startups that want to bring fantastic and innovative developments into the market. Are you an entrepreneur within Life Science & Health with an early stage seed venture and are you looking for an investment (TRL2-7)? Submit your proposal via our application portal. Do you have a question? Please contact us via email@example.com.
The Utrecht Health Seed Fund is a joint initiative established by Utrecht Holdings and the Economic Board Utrecht (EBU) with the assistance and support of the EU’s European Regional Development Fund (ERDF), co-financing of the Dutch Government and support of UMC Utrecht, and the University of Utrecht.
Utrecht Holdings manages the UHSF. Utrecht Holdings has an extensive track record in the field of early-stage life sciences and health investment.